Mark Ratain

2 months ago | statnews.com | Mark Ratain

The current paradigm of government-funded cancer clinical trials — doing industry’s work for it — is not working for taxpayers.

Sep 26, 2024 | ejcancer.com | Sanjay Popat |Mark Ratain

Get full text accessLog in, subscribe or purchase for full access. References1. Skoulidis, F. ∙ Li, B.T. ∙ Dy, G.K. ... Sotorasib for Lung Cancers with KRAS p.G12C MutationN Engl J Med. 2021; 384:2371-23812. de Langen, A.J. ∙ Johnson, M.L. ∙ Mazieres, J. ... Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401:733-7463. FDA.

Apr 11, 2024 | ascpt.onlinelibrary.wiley.com | Mark Ratain |Pharmacogenomics The

While therapeutic drug monitoring is a potentially attractive strategy that can be utilized by clinical pharmacologists to optimize drug dosing, the costs and risks must be balanced against the potential benefits. However, there is great uncertainty regarding the optimal population dose for most oncology drugs, given the lack of randomized dose-ranging phase II trials. Therefore, efforts to individualize dosing are for the most part premature for such agents.

Aug 15, 2023 | statnews.com | Mark Ratain

As STAT reported recently, the Senate Committee on Health, Education, Labor, and Pensions (HELP) has indicated that it will not consider the nomination of Monica Bertagnolli as director of the National Institutes of Health unless she pledges to take specific steps to reduce drug prices. However, the HELP Committee may want to focus on reducing drug spending, the product of price and units prescribed, rather than simply pricing.